Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China’s NMPA Steps Up To The Plate In COVID-19 Fight But Much Is Left To Do

Executive Summary

Chinese monitoring of the spread of COVID-19 locally has reported no new cases of home-grown infection in a single day for the first time since the outbreak began. It indicates control efforts, including the NMPA’s fast-tracking of relevant devices, PPE and IVDs, are having the desired effects.

You may also be interested in...



APACMed 2020: Dynamic China Market Will Heed COVID-19 Lessons For System Improvement In '21

To the watching world, China dealt quickly and firmly with COVID-19. Seen from within, the health care system is still adapting to the pandemic, but the government is taking the longer view.

MTI 2022 Outlook: The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize

Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the leading global medtechs share their perspectives on the present and the future, from company and health care system standpoints.

Medtechs Drive To Keep The Status Quo In A Year Like No Other

The performances of the leading medtechs in the first year of the COVID-19 pandemic were impossible to compare and certainly unrepresentative of normal business cycles and competitive activity. Elective care was largely put on hold and emergency needs boosted exceptional demand for certain product types. More than anything else, 2020 tested management skills and planning.

Topics

UsernamePublicRestriction

Register

MT126428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel